SCHEMBL2932922

SCHEMBL2932922

O=C(c1ccco1)N1CC[N]CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.66
NPSR1 Q6W5P4 3/20 0.66
HTT P42858 1/20 0.66
TSHR P16473 2/20 0.65
TP53 P04637 1/20 0.65
MAPK1 P28482 1/20 0.64
HSD17B10 Q99714 1/20 0.61
LMNA P02545 4/20 0.60
SMN1; SMN2 Q16637 3/20 0.59
GAA P10253 2/20 0.59
PKM P14618 1/20 0.59
CYP1A2 P05177 1/20 0.57
POLB P06746 1/20 0.57
KDM4E B2RXH2 1/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
MAPT P10636 2/20 0.56
KMT2A Q03164 1/20 0.56
CYP2C9 P11712 1/20 0.56
ALOX12 P18054 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16026437 0.87 ALDH1A1 (0.83) ALDH1A1NPSR1HTTTSHRTP53
SCHEMBL4748498 0.82 ALDH1A1 (0.87) ALDH1A1NPSR1HTTTSHRTP53
SCHEMBL61103 0.82 ALDH1A1 (0.87) ALDH1A1NPSR1HTTTSHRTP53
SCHEMBL1372144 0.81 ALDH1A1 (0.73) ALDH1A1NPSR1HTTTSHRTP53
SCHEMBL3099181 0.81 ALDH1A1 (0.73) ALDH1A1NPSR1HTTTSHRTP53
SCHEMBL1275334 0.81 ALDH1A1 (0.68) ALDH1A1NPSR1HTTTSHRTP53
SCHEMBL9792219 0.81 ALDH1A1 (0.88) ALDH1A1NPSR1HTTTSHRTP53
SCHEMBL3093579 0.79 ALDH1A1 (0.71) ALDH1A1NPSR1HTTTSHRTP53
SCHEMBL13804475 0.79 ALDH1A1 (0.71) ALDH1A1NPSR1HTTTSHRTP53
SCHEMBL28752 0.79 ALDH1A1 (0.66) ALDH1A1NPSR1HTTTSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010022055-A2 INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2010-02-25 WO claimed
US-20080194545-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE TRIUS THERAPEUTICS (US) 2008-08-14 US claimed
WO-2008098143-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF USE TRIUS THERAPEUTICS (US) 2008-08-14 WO claimed
EP-1865963-A2 TRIAZADIBENZOAZULENE COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR Acadia Pharmaceuticals Inc. (US) 2007-12-19 EP claimed
EP-1144384-B1 COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARM INC (US) 2007-10-31 EP claimed
US-20060217370-A1 Compounds useful for the treatment and prevention of pain and screening methods therefor ACADIA PHARMACEUTICALS INC. 2006-09-28 US claimed
WO-2006089286-A2 TRIAZADIBENZOAZULENE COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR ACADIA PHARMACEUTICALS INC. (US) 2006-08-24 WO claimed
US-6515122-B1 The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing tetracyclic benzimidazole derivative compounds. LION BIOSCIENCE AG (DE) 2003-02-04 US claimed
EP-1218384-A4 TETRACYCLIC BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2002-11-20 EP claimed
US-6417195-B1 LIBRARIES AND COMBINATORIAL CHEMISTRY LION BIOSCIENCE AG (DE) 2002-07-09 US claimed
EP-1019367-A1 DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-07-19 EP claimed
WO-1999007672-A1 DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1999-02-18 WO claimed
EP-0083315-B1 PYRIDYL-N-OXIDES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CIBA-GEIGY AG (CH) 1987-07-29 EP claimed
US-4656174-A HYPOTENSIVE AGENTS PFIZER INC. (US) 1987-04-07 US claimed
EP-0200024-A2 3-Cyano-pyridines, process for their preparation and their pharmaceutical use ARZNEIMITTELWERK DRESDEN GmbH (DE) 1986-11-05 EP claimed
EP-0163240-A2 Dihydroimidazo[1,2-a]pyrimidine derivatives, methods of preparing said compounds and pharmaceutical compositions constaining said compounds Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1985-12-04 EP claimed
US-4497808-A N-Oxide compounds useful in the treatment of cardiovascular ailments CIBA-GEIGY CORPORATION (US) 1985-02-05 US claimed
EP-0111453-A1 Amide derivatives CIBA-GEIGY AG (CH) 1984-06-20 EP claimed
EP-0111455-A2 Unsaturated lactones CIBA-GEIGY AG (CH) 1984-06-20 EP claimed
EP-0083315-A2 Pyridyl-N-oxides, processes for their preparation and pharmaceutical compositions containing them CIBA-GEIGY AG (CH) 1983-07-06 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194545-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE ABCB11, FPR1, C5 ALDH1A1 1135/4885NPSR1 2356/4885HTT 2777/4885
US-20060217370-A1 Compounds useful for the treatment and prevention of pain and screening methods therefor ACHE, OPRL1, OPRK1 ALDH1A1 634/4885NPSR1 258/4885HTT 1866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.